CAPR NASDAQ
Capricor Therapeutics, Inc.
1W: -7.7%
1M: -30.0%
3M: -7.2%
YTD: -78.5%
1Y: -1.6%
3Y: +121.0%
5Y: +54.0%
$6.10
+0.36 (+6.27%)
Weekly Expected Move ±13.9%
$4
$5
$6
$7
$8
Credit Risk of going bust: higher than 97% of companies Debt: 20.5% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the riskiest tenth, about 1 in 20 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.55 (down 91%), Capricor Therapeutics, Inc. would be worth roughly what it owes.
Total debt $91.0M against a stock market value of $353.3M.
Distance to default 0.05 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $45.5M (short-term plus half of long-term), stock volatility 216.5%; Altman Z'' 0.17. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.55 (down 91%), Capricor Therapeutics, Inc. would be worth roughly what it owes.
Total debt $91.0M against a stock market value of $353.3M.
Distance to default 0.05 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $45.5M (short-term plus half of long-term), stock volatility 216.5%; Altman Z'' 0.17. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$353.3M
52W Range2.96-40.37
Volume3,462,805
Avg Volume5,493,213
Beta0.53
Dividend—
Analyst Ratings
Company Info
CEOLinda Marbán
Employees231
SectorHealthcare
IndustryBiotechnology
IPO Date2007-02-13
Websitecapricor.com
10865 Road to the Cure
San Diego, CA 92121
US
San Diego, CA 92121
US
310 358 3200
About Capricor Therapeutics, Inc.
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (âDMDâ), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.
Latest News
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Stock Rated “Hold” by Wall Street Brokerages
Capricor drops as deramiocel OLE data fails to quell regulatory concerns
Short Interest Alert: Most and least shorted sub-$2B healthcare stocks in Sep. 2026
Capricor Therapeutics (NASDAQ:CAPR) Shares Gap Up – Here’s Why
Capricor jumps as study shows longer-term effects of deramiocel
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Krasney Karen | S-Sale | 24,100 | $30.38 | 2026-06-25 |
| Bergmann Anthony | S-Sale | 24,100 | $30.38 | 2026-06-25 |
| Krasney Karen | S-Sale | 400 | $30.00 | 2026-06-24 |
| Bergmann Anthony | S-Sale | 400 | $30.00 | 2026-06-24 |
| Maurer Michael T | A-Award | 80,000 | $29.36 | 2026-05-26 |